Inicio
Markets
Charts & Ideas
Algo
Noticias
Store
Corredores
Descargar
Calendario económico
Señales Comerciales
WebTerminal
Pulse
/
para buscar: @user, $symbol, ...
Buscar
Entrada
Crear una cuenta
日本語
English
Русский
中文
Español
Português
Deutsch
한국어
Français
Italiano
Türkçe
CCCC
#2959
C4 Therapeutics, Inc.
2.7
0
-1.46%
Sector:
Básica:
Profit Currency:
Rango diario
Rango anual
Cambio diario
-1.46%
Monthly Change
+26.17%
6 month change
+5.06%
Cambio anual
+4.25%
Cierres anteriores
2.7
4
Open
2.7
0
Bid
Ask
Low
2.7
0
High
2.7
0
Volumen
57
Markets
Acciones
Atención Sanitaria
CCCC
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
Q4, 25
TTM
Key stats
Total common shares outstanding
70.59 M
70.99 M
71.01 M
71.17 M
96.91 M
97.58 M
—
Valuation ratios
Enterprise value
342.71 M
200.06 M
62.32 M
23.62 M
156.34 M
111.77 M
354.05 M
Price to earnings ratio
-3.35
-2.37
-1.08
-0.9
-1.32
-1.5
-4.81
Price to sales ratio
11.28
7.02
2.8
2.93
5.25
—
—
Price to cash flow ratio
4.88
3.83
1.39
1.15
1.67
1.6
5.82
Price to book ratio
0.36
1.16
0.12
0.12
0.21
0.62
1.07
Enterprise value to EBITDA ratio
—
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.07
0.1
0.08
0.09
0.12
0.06
0.35
Return on equity %
0.1
0.16
0.13
0.15
0.21
0.08
0.57
Return on invested capital %
76.84
112.39
92.51
98.05
140.69
87
418.25
Gross margin %
100
100
100
100
100
100
400
Operating margin %
183.86
728.39
402.93
440.99
306.43
210.1
1 360.45
EBITDA margin %
—
—
—
—
—
—
—
Net margin %
160.57
667.82
363.66
402.6
286.43
185.97
1 238.66
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
6.31
5.71
5.7
5.06
5.76
7.81
24.32
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0.04
0.01
0.02
0.02
0.04
0.04
0.12
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
0.35
0.26
0.47
0.17
0.43
0.27
1.34
EBIT per share
—
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
—
Cash per share
4.08
3.85
3.31
3.14
2.75
3.58
12.79
Net current asset value per share
3.92
3.72
3.28
3.16
2.85
3.11
12.41
Tangible book value per share
3.49
3.11
2.75
2.45
2.13
3.1
10.43
Working capital per share
3.3
3.06
2.71
2.54
2.36
2.72
10.32
Book value per share
3.49
3.11
2.75
2.45
2.13
3.1
10.43
Noticias
Barclaysが臨床試験の進展を受けてC4 Therapeuticsの目標株価を引き上げ
Barclays raises C4 Therapeutics stock price target on trial progress
TD Cowen、C4 Therapeuticsに対する買い推奨を継続
TD Cowen reiterates Buy rating on C4 Therapeutics stock
【決算速報】C4 セラピューティクス、売上高は予想を上回り、利益は予想を上回る結果に
C4 earnings beat by $0.11, revenue topped estimates
ブルックライン・キャピタル、治験進展を受けC4 Therapeutics株の目標株価を引き上げ
Brookline Capital raises C4 Therapeutics stock price target on trial progress
C4 Therapeutics doses first patient in phase 2 myeloma trial
C4セラピューティクスのレイノ最高医療責任者、2.22万ドル相当の株式を売却
C4 Therapeutics’ chief medical officer Reyno sells $22,200 in stock
C4セラピューティクス、多発性骨髄腫向けセムシドミド臨床試験を推進へ